Low-dose blinatumomab for severe autoimmune brain inflammation
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a low-dose medication called blinatumomab (a type of immunotherapy) to see if it can help people with severe, treatment-resistant autoimmune encephalitis or autoimmune cerebellitis. It aims to calm the immune system's attack on the brain, potentially improving symptoms when standard treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed antibody-positive diagnosis of autoimmune encephalitis or autoimmune cerebellitis.
- Your symptoms must be severe (e.g., needing help with daily activities) and have not improved despite at least one round of first-line treatments like steroids, IVIG (immune globulin), or plasma exchange.
- You must have tried at least one additional immunotherapy (like rituximab, mycophenolate, cyclophosphamide, azathioprine, or long-term steroids) for at least 2 months without improvement.
- You must be generally healthy otherwise — no active infections, cancer (except certain cured types), or serious heart, liver, or kidney problems.
- You must agree to use effective birth control during the trial and for 3 months after the last dose if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving medicine into the spinal fluid (intrathecal chemotherapy) to lower the risk of brain/nerve side effects from blinatumomab. It’s for adults with certain types of B-cell acute lymphoblastic leukemia (ALL) who are starting their first cycle.
This trial tests a drug called blinatumomab for children with active lupus that hasn't improved with standard treatments. It aims to see if this immunotherapy can help calm the immune system and reduce lupus activity.
This trial is testing a new medication called blinatumomab for people with difficult-to-treat myasthenia gravis, a condition that causes muscle weakness. The drug aims to help reduce symptoms and improve quality of life for those who haven't improved with standard treatments.
This trial tests a new treatment for people with generalized myasthenia gravis (a condition causing muscle weakness) that hasn't improved with standard medications. The treatment, called blinatumomab, aims to reduce weakness by targeting certain immune cells.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
This trial tests a new way to give blinatumomab (a drug that helps your immune system fight cancer) as a shot under the skin for a rare leukemia called MPAL. It includes three different groups of patients depending on their treatment history.
Hear when a new Autoimmune Encephalitis (AE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.